Does Otrexup Cause Liver Enzyme Elevation?
Yes, Otrexup (methotrexate injection) can cause liver enzyme elevation. Methotrexate is known to be hepatotoxic, with elevated liver enzymes (such as ALT and AST) reported in clinical use. The prescribing information lists hepatotoxicity as a common adverse reaction, occurring in up to 15-20% of patients on low-dose regimens like those for rheumatoid arthritis. Monitoring liver function tests is required before, during, and after treatment to detect elevations early.[1][2]
How Common Is Liver Enzyme Elevation with Otrexup?
In post-marketing data and trials, mild to moderate elevations occur frequently—often within the first few months of therapy. Severe cases leading to fibrosis or cirrhosis are rarer (about 1-3% with long-term use) but more likely in patients with risk factors like alcohol use, obesity, diabetes, or concurrent NSAIDs. Weekly dosing via Otrexup's auto-injector doesn't alter this risk profile compared to oral methotrexate.[1][3]
Why Does Methotrexate Raise Liver Enzymes?
Methotrexate inhibits dihydrofolate reductase, disrupting DNA synthesis and causing oxidative stress in hepatocytes. This leads to inflammation and enzyme leakage. Folic acid supplementation (required with Otrexup) reduces but doesn't eliminate the risk.[2][4]
What Should Patients Watch For?
Symptoms include fatigue, nausea, jaundice, or right upper quadrant pain. Providers recommend baseline LFTs, then every 1-3 months initially, and less often if stable. Discontinue if enzymes exceed 2-3 times the upper limit of normal.[1][5]
Who Is at Higher Risk?
Patients with pre-existing liver disease, heavy alcohol use (>1-2 drinks/day), or viral hepatitis face amplified risk. Avoid in active liver disease; use caution with hepatotoxic drugs like azathioprine.[2]
How Does This Compare to Other Methotrexate Forms?
Otrexup's subcutaneous delivery may cause slightly fewer GI issues than oral forms, but liver enzyme elevations occur at similar rates (10-30% incidence). No head-to-head trials show differences.[3]
Management and Alternatives
Dose reduction, folate increase, or temporary hold often resolves elevations. Alternatives include leflunomide or biologics like Humira for RA/psoriasis, with lower hepatotoxicity but higher cost.[4][5]
[1]: Otrexup Prescribing Information (FDA)
[2]: Methotrexate Hepatotoxicity Review (UpToDate)
[3]: RA Trial Data on Methotrexate (Arthritis Rheum)
[4]: DrugPatentWatch.com - Otrexup Patents (no liver-specific patents noted)
[5]: ACR Guidelines for Methotrexate Monitoring